Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, SonALAsense is raising $30,093,202.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Mark DeSouza played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SonALAsense
SonALAsense is a clinical-stage company developing ALA sonodynamic therapy (SDT) as a first-in-class, non-invasive drug-device combination for the treatment of recurrent glioblastoma multiforme (rGBM) and other deadly cancers. SDT utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells.

To learn more about SonALAsense, visit http://sonalasense.com/

Contact:
Mark DeSouza, Chief Operating Officer
925-466-4554
https://www.linkedin.com/in/mark-de-souza-196941a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved